Literature DB >> 24155398

Control of simian immunodeficiency virus replication by vaccine-induced Gag- and Vif-specific CD8+ T cells.

Nami Iwamoto1, Naofumi Takahashi, Sayuri Seki, Takushi Nomura, Hiroyuki Yamamoto, Makoto Inoue, Tsugumine Shu, Taeko K Naruse, Akinori Kimura, Tetsuro Matano.   

Abstract

For development of an effective T cell-based AIDS vaccine, it is critical to define the antigens that elicit the most potent responses. Recent studies have suggested that Gag-specific and possibly Vif/Nef-specific CD8(+) T cells can be important in control of the AIDS virus. Here, we tested whether induction of these CD8(+) T cells by prophylactic vaccination can result in control of simian immunodeficiency virus (SIV) replication in Burmese rhesus macaques sharing the major histocompatibility complex class I (MHC-I) haplotype 90-010-Ie associated with dominant Nef-specific CD8(+) T-cell responses. In the first group vaccinated with Gag-expressing vectors (n = 5 animals), three animals that showed efficient Gag-specific CD8(+) T-cell responses in the acute phase postchallenge controlled SIV replication. In the second group vaccinated with Vif- and Nef-expressing vectors (n = 6 animals), three animals that elicited Vif-specific CD8(+) T-cell responses in the acute phase showed SIV control, whereas the remaining three with Nef-specific but not Vif-specific CD8(+) T-cell responses failed to control SIV replication. Analysis of 18 animals, consisting of seven unvaccinated noncontrollers and the 11 vaccinees described above, revealed that the sum of Gag- and Vif-specific CD8(+) T-cell frequencies in the acute phase was inversely correlated with plasma viral loads in the chronic phase. Our results suggest that replication of the AIDS virus can be controlled by vaccine-induced subdominant Gag/Vif epitope-specific CD8(+) T cells, providing a rationale for the induction of Gag- and/or Vif-specific CD8(+) T-cell responses by prophylactic AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24155398      PMCID: PMC3911762          DOI: 10.1128/JVI.02634-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

Authors:  Marcus Altfeld; Marylyn M Addo; Eric S Rosenberg; Frederick M Hecht; Paul K Lee; Martin Vogel; Xu G Yu; Rika Draenert; Mary N Johnston; Daryld Strick; Todd M Allen; Margaret E Feeney; James O Kahn; Rafick P Sekaly; Jay A Levy; Jürgen K Rockstroh; Philip J Goulder; Bruce D Walker
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

2.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma.

Authors:  Bradley H Edwards; Anju Bansal; Steffanie Sabbaj; Janna Bakari; Mark J Mulligan; Paul A Goepfert
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model.

Authors:  Akiko Takeda; Hiroko Igarashi; Hiromi Nakamura; Munehide Kano; Akihiro Iida; Takahiro Hirata; Mamoru Hasegawa; Yoshiyuki Nagai; Tetsuro Matano
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.

Authors:  Jianming Tang; Shenghui Tang; Elena Lobashevsky; Angela D Myracle; Ulgen Fideli; Grace Aldrovandi; Susan Allen; Rosemary Musonda; Richard A Kaslow
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

8.  MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Thorsten Mühl; Michael Krawczak; Peter Ten Haaft; Gerhard Hunsmann; Ulrike Sauermann
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

9.  Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection.

Authors:  V Novitsky; P Gilbert; T Peter; M F McLane; S Gaolekwe; N Rybak; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8+ T-cell responses in SIVmac239 infection of Burmese rhesus macaques.

Authors:  Naofumi Takahashi; Takushi Nomura; Yusuke Takahara; Hiroyuki Yamamoto; Teiichiro Shiino; Akiko Takeda; Makoto Inoue; Akihiro Iida; Hiroto Hara; Tsugumine Shu; Mamoru Hasegawa; Hiromi Sakawaki; Tomoyuki Miura; Tatsuhiko Igarashi; Yoshio Koyanagi; Taeko K Naruse; Akinori Kimura; Tetsuro Matano
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more
  18 in total

1.  Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.

Authors:  Mauro Di Pilato; Ernesto Mejías-Pérez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  A Novel Immunogen Selectively Eliciting CD8+ T Cells but Not CD4+ T Cells Targeting Immunodeficiency Virus Antigens.

Authors:  Hiroshi Ishii; Kazutaka Terahara; Takushi Nomura; Akiko Takeda; Midori Okazaki; Hiroyuki Yamamoto; Tsuyoshi Tokusumi; Tsugumine Shu; Tetsuro Matano
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

3.  Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection.

Authors:  Kazutaka Terahara; Hiroshi Ishii; Takushi Nomura; Naofumi Takahashi; Akiko Takeda; Teiichiro Shiino; Yasuko Tsunetsugu-Yokota; Tetsuro Matano
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

4.  Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction.

Authors:  Justin De La Cruz; Thomas Vollbrecht; Patricia Frohnen; Hwee L Ng; Eric S Daar; Otto O Yang; Martha J Lewis
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

5.  Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Authors:  Mauricio A Martins; Damien C Tully; Núria Pedreño-Lopez; Benjamin von Bredow; Matthias G Pauthner; Young C Shin; Maoli Yuan; Noemia S Lima; David J Bean; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; John D Altman; Dennis R Burton; Keisuke Ejima; David B Allison; David T Evans; Eva G Rakasz; Christopher L Parks; Myrna C Bonaldo; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

6.  NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Authors:  Mauro Di Pilato; Ernesto Mejías-Pérez; Manuela Zonca; Beatriz Perdiguero; Carmen Elena Gómez; Marianna Trakala; Jacobo Nieto; José Luis Nájera; Carlos Oscar S Sorzano; Christophe Combadière; Giuseppe Pantaleo; Lourdes Planelles; Mariano Esteban
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-04       Impact factor: 11.205

7.  Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells.

Authors:  Hiroshi Ishii; Kazutaka Terahara; Takushi Nomura; Midori Okazaki; Hiroyuki Yamamoto; Tsugumine Shu; Hiromi Sakawaki; Tomoyuki Miura; David I Watkins; Tetsuro Matano
Journal:  Mol Ther       Date:  2022-02-26       Impact factor: 12.910

8.  Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.

Authors:  Sumire Iseda; Naofumi Takahashi; Hugo Poplimont; Takushi Nomura; Sayuri Seki; Taku Nakane; Midori Nakamura; Shoi Shi; Hiroshi Ishii; Shota Furukawa; Shigeyoshi Harada; Taeko K Naruse; Akinori Kimura; Tetsuro Matano; Hiroyuki Yamamoto
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

9.  Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

Authors:  Mauricio A Martins; Nancy A Wilson; Shari M Piaskowski; Kim L Weisgrau; Jessica R Furlott; Myrna C Bonaldo; Marlon G Veloso de Santana; Richard A Rudersdorf; Eva G Rakasz; Karen D Keating; Maria J Chiuchiolo; Michael Piatak; David B Allison; Christopher L Parks; Ricardo Galler; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

10.  HLA-associated preadaptation in HIV Vif is associated with higher set point viral load and faster CD4+ decline in Zambian transmission pairs.

Authors:  Sarah Connolly; Jonathan M Carlson; Malinda Schaefer; Alfred Bere; William Kilembe; Susan Allen; Eric Hunter
Journal:  AIDS       Date:  2021-07-01       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.